Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eileen Dolan

Showing results (71-80 of 188) with videos related to

Pageof 19
Sort By:
Physiological Genomics|August 8, 2013
Cell cycle arrest in a model of colistin nephrotoxicityMichael T Eadon, Bradley K Hack, Jessy J Alexander, et al.
Chemical Research in Toxicology|March 19, 2002
Modified guanines representing O(6)-alkylation by the cyclophosphamide metabolites acrolein and chloroacetaldehyde: synthesis, stability, and ab initio studiesNarayanan Balu, Michael P Gamcsik, Michael E Colvin, et al.
Biochemical Pharmacology|December 6, 2005
Role of GADD34 in modulation of cisplatin cytotoxicityMelissa L Fishel, Cara A Rabik, Wasim K Bleibel, et al.
Epigenetics|July 17, 2015
Characterization of CpG sites that escape methylation on the inactive human X-chromosomeErika L Moen, Edward Litwin, Stephen Arnovitz, et al.
Pharmacogenetics and Genomics|June 7, 2011
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studiesYujia Wen, Lidija K Gorsic, Heather E Wheeler, et al.
Pharmacogenomics|September 13, 2013
Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation scienceM Eileen Dolan, Michael L Maitland, Peter H O'Donnell, et al.
Plos One|December 25, 2013
EPS8 inhibition increases cisplatin sensitivity in lung cancer cellsLidija K Gorsic, Amy L Stark, Heather E Wheeler, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2003
Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cellsSonali M Smith, Susan M Ludeman, Lynette R Wilson, et al.
Plos Genetics|February 21, 2012
Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancerHae Kyung Im, Eric R Gamazon, Amy L Stark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumorsM Eileen Dolan, Mitchell Posner, Theodore Karrison, et al.
Pageof 19

Showing results (71-80 of 188) with videos related to

Sort By:
Pageof 19
Physiological Genomics|August 8, 2013
Cell cycle arrest in a model of colistin nephrotoxicityMichael T Eadon, Bradley K Hack, Jessy J Alexander, et al.
Chemical Research in Toxicology|March 19, 2002
Modified guanines representing O(6)-alkylation by the cyclophosphamide metabolites acrolein and chloroacetaldehyde: synthesis, stability, and ab initio studiesNarayanan Balu, Michael P Gamcsik, Michael E Colvin, et al.
Biochemical Pharmacology|December 6, 2005
Role of GADD34 in modulation of cisplatin cytotoxicityMelissa L Fishel, Cara A Rabik, Wasim K Bleibel, et al.
Epigenetics|July 17, 2015
Characterization of CpG sites that escape methylation on the inactive human X-chromosomeErika L Moen, Edward Litwin, Stephen Arnovitz, et al.
Pharmacogenetics and Genomics|June 7, 2011
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studiesYujia Wen, Lidija K Gorsic, Heather E Wheeler, et al.
Pharmacogenomics|September 13, 2013
Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation scienceM Eileen Dolan, Michael L Maitland, Peter H O'Donnell, et al.
Plos One|December 25, 2013
EPS8 inhibition increases cisplatin sensitivity in lung cancer cellsLidija K Gorsic, Amy L Stark, Heather E Wheeler, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2003
Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cellsSonali M Smith, Susan M Ludeman, Lynette R Wilson, et al.
Plos Genetics|February 21, 2012
Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancerHae Kyung Im, Eric R Gamazon, Amy L Stark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumorsM Eileen Dolan, Mitchell Posner, Theodore Karrison, et al.
Pageof 19